These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 38217869)

  • 1. Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity.
    Núñez-Sánchez MÁ; Martínez-Sánchez MA; Martínez-Montoro JI; Balaguer-Román A; Murcia-García E; Fernández-Ruiz VE; Ferrer-Gómez M; Martínez-Cáceres CM; Sledzinski T; Frutos MD; Hernández-Morante JJ; Fernández-García JC; Queipo-Ortuño MI; Ruiz-Alcaraz AJ; Mika A; Ramos-Molina B
    J Clin Endocrinol Metab; 2024 Jun; 109(7):1781-1792. PubMed ID: 38217869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver tissue lipids in metabolic dysfunction-associated steatotic liver disease with diabetes and obesity.
    Sourianarayanane A; Brydges CR; McCullough AJ
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102402. PubMed ID: 38909684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of PCSK9 in metabolic dysfunction-associated steatotic liver disease and its impact on bariatric surgery outcomes.
    Castellano-Castillo D; Núñez-Sánchez MÁ; Balaguer-Román A; Martínez-Sánchez MA; Fernández-Ruiz VE; Ferrer-Gómez M; Martínez CM; Frutos MD; Queipo-Ortuño MI; Cardona F; Ramos-Molina B
    Surg Obes Relat Dis; 2024 Jul; 20(7):652-659. PubMed ID: 38490825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
    Soto-Catalán M; Opazo-Ríos L; Quiceno H; Lázaro I; Moreno JA; Gómez-Guerrero C; Egido J; Mas-Fontao S
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatial lipidomics reveals zone-specific hepatic lipid alteration and remodeling in metabolic dysfunction-associated steatohepatitis.
    Seubnooch P; Montani M; Dufour JF; Masoodi M
    J Lipid Res; 2024 Sep; 65(9):100599. PubMed ID: 39032559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease.
    Kjeldsen SAS; Werge MP; Grandt J; Richter MM; Thing M; Hetland LE; Rashu EB; Jensen AH; Winther-Sørensen M; Kellemann JS; Holst JJ; Junker AE; Serizawa RR; Vyberg M; Gluud LL; Wewer Albrechtsen NJ
    Am J Physiol Gastrointest Liver Physiol; 2024 Oct; 327(4):G558-G570. PubMed ID: 39104323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Dysfunction-Associated Steatotic Liver Disease in Severe Obesity and Concordance between Invasive (Biopsy) and Noninvasive (OWLiver®) Diagnoses.
    Navarro-Masip È; Mestres Petit N; Salinas-Roca B; Herrerías F; Vilardell F; de la Fuente MC; Pallares J; Santamaría M; Zorzano-Martínez M; Sánchez E; Matías-Guiu X; López-Cano C; Soler AG; León-Mengíbar J; Bueno M; Lecube A
    Obes Facts; 2024; 17(5):473-482. PubMed ID: 38934179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD.
    Sabinari I; Horakova O; Cajka T; Kleinova V; Wieckowski MR; Rossmeisl M
    Physiol Res; 2024 Aug; 73(Suppl 1):S295-S320. PubMed ID: 39016154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic angiotensin-converting enzyme 2 expression in metabolic dysfunction-associated steatotic liver disease and in patients with fatal COVID-19.
    Jacobs AK; Morley SD; Samuel K; Morgan K; Boswell L; Kendall TJ; Dorward DA; Fallowfield JA; Hayes PC; Plevris JN
    World J Gastroenterol; 2024 Aug; 30(31):3705-3716. PubMed ID: 39192998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triglyceride to HDL Cholesterol Ratio for the Identification of MASLD in Obesity: A Liver Biopsy-Based Case-Control Study.
    Martínez-Montoro JI; Martínez-Sánchez MA; Balaguer-Román A; Fernández-Ruiz VE; Hernández-Barceló JE; Ferrer-Gómez M; Frutos MD; Núñez-Sánchez MÁ; Fernández-García JC; Ramos-Molina B
    Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease.
    Núñez-Sánchez MÁ; Martínez-Sánchez MA; Sierra-Cruz M; Lambertos A; Rico-Chazarra S; Oliva-Bolarín A; Balaguer-Román A; Yuste JE; Martínez CM; Mika A; Frutos MD; Llamoza-Torres CJ; Córdoba-Chacón J; Ramos-Molina B
    J Pathol; 2024 Sep; 264(1):101-111. PubMed ID: 39022853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BDE-47 induces metabolic dysfunction-associated steatotic liver disease (MASLD) through CD36-mediated increased fatty acid uptake and PPARα-induced abnormal fatty acid oxidation in BALB/c mice.
    Xia B; Yu R; Liu J; Liu D; Li S; Yang L; Liu N; Liang B; Zeng J; Wei J; Lin G
    Toxicol Lett; 2024 Jan; 391():100-110. PubMed ID: 38040069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity.
    Walle P; Takkunen M; Männistö V; Vaittinen M; Lankinen M; Kärjä V; Käkelä P; Ågren J; Tiainen M; Schwab U; Kuusisto J; Laakso M; Pihlajamäki J
    Metabolism; 2016 May; 65(5):655-666. PubMed ID: 27085774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Odds of Metabolic Dysfunction-Associated Steatotic Liver Disease Are Linked to Reduced n-6, but Not n-3 Polyunsaturated Fatty Acids in Plasma.
    Frankovic I; Djuricic I; Ninic A; Vekic J; Vorkapic T; Erceg S; Gojkovic T; Tomasevic R; Mamic M; Mitrovic M; Zeljkovic A
    Biomolecules; 2024 Jul; 14(8):. PubMed ID: 39199290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic profiling of tryptophan pathways: Implications for obesity and metabolic dysfunction-associated steatotic liver disease.
    Arto C; Rusu EC; Clavero-Mestres H; Barrientos-Riosalido A; Bertran L; Mahmoudian R; Aguilar C; Riesco D; Chicote JU; Parada D; Martínez S; Sabench F; Richart C; Auguet T
    Eur J Clin Invest; 2024 Nov; 54(11):e14279. PubMed ID: 38940215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiomics analyses decipher intricate changes in the cellular and metabolic landscape of steatotic livers upon dietary restriction and sleeve gastrectomy.
    Chen S; Zeng Q; Cai X; Xue J; Yin G; Song P; Tang L; Klein C; Tacke F; Guillot A; Liu H
    Int J Biol Sci; 2024; 20(11):4438-4457. PubMed ID: 39247824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.
    López-Pascual E; Rienda I; Perez-Rojas J; Rapisarda A; Garcia-Llorens G; Jover R; Castell JV
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the Regulatory Effect of LPJZ-658 on Copper Deficiency Combined with Sugar-Induced MASLD in Middle-Aged Mice Based on Multi-Omics Analysis.
    Li C; Liu Z; Wei W; Chen C; Zhang L; Wang Y; Zhou B; Liu L; Li X; Zhao C
    Nutrients; 2024 Jun; 16(13):. PubMed ID: 38999758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
    Huttasch M; Roden M; Kahl S
    Metabolism; 2024 Aug; 157():155937. PubMed ID: 38782182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.